You are here

Article Text

Article menu
Download PDFPDF
Letter
Gastrointestinal cancer pathways may breakdown due to COVID-19
  1. Ajay M Verma1,
  2. Jasmine Kaur Nagpal2
  1. 1 Department of Digestive Diseases, Kettering General Hospital NHS Foundation Trust, Kettering, UK
  2. 2 Southwark Primary Care, Nexus Health Group, London, UK
  1. Correspondence to Dr Ajay M Verma, Digestive Diseases, Kettering General Hospital NHS Foundation Trust, Kettering NN16 8UZ, UK; ajay.verma{at}nhs.net

https://doi.org/10.1136/flgastro-2020-101569

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In 2018/2019, 587 517 patients in England were referred on an urgent gastrointestinal (GI) two-week-wait (2WW) cancer pathway.1 Patients attend straight-to-test endoscopy procedures, or urgent clinic appointments.

    Upper GI cancer pathways have a cancer yield of 3%, lower GI 7%.2 General practitioners (GPs) and hospital clinicians are accustomed to a high volume of referrals with low yield. This has been mutually beneficial, improving GI cancer outcomes for the population, ease of referral in primary care, and generating income for secondary care. Consequently, the majority of patients investigated have benign conditions. These services are pressured due to significant resource and workforce constraints, 90% of patients in 2018/2019 were seen within 14 days (target 93%).1

    COVID-19 swept through Europe killing tens of thousands. The peak …

    View Full Text